Pascal Ghoson News Today

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM - May 27, 2024 - 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

` Important Advances in Oxurions R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV , an innovative biopharmaceutical company based in...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET , a biopharmaceutical company headquartered in Leuven, today...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,75...

10.04.2024 - Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, ...

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program

Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV , a biopharmaceutical company headquartered in Leuven, today made...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC